Search results
Results from the WOW.Com Content Network
Antibacterial mouth rinse, Clinical follow-up on a quarterly basis, Patient education and review of indications for continued bisphosphonate therapy Stage 2 Exposed and necrotic bone, or fistulae that probes to bone, associated with infection as evidenced by pain and erythema in the region of the exposed bone with or without purulent drainage
Prolia, approved in 2010 to treat bone loss in postmenopausal women and later approved to treat men and women at high risk of fracture, brought in total third-quarter sales of $986 million.
Ibandronic acid is a bisphosphonate medication used in the prevention and treatment of osteoporosis and metastasis-associated skeletal fractures in people with cancer. [4] It may also be used to treat hypercalcemia (elevated blood calcium levels). It is typically formulated as its sodium salt ibandronate sodium. [medical citation needed]
In June 2010, denosumab was approved by the FDA for use in postmenopausal women with risk of osteoporosis [37] under the brand name Prolia, [38] and in November 2010, as Xgeva for the prevention of skeleton-related events in people with bone metastases from solid tumors. [39] Denosumab is the first RANKL inhibitor to be approved by the FDA. [37]
Osteoporosis drugs taken to prevent bone fracture may cause rare, but critical, fractures of their own, the Food and Drug Administration announced today in a warning to consumers. The agency also ...
Prolia (denosumab) is an injectable medication that helps treat osteoporosis. Osteoporosis is a condition that causes the bones to become thin and weak, leading to a higher risk of fractures and ...
Specific examples include familial hypercoagulation, diabetes, autoimmune diseases, Agranulocytosis, leukemia, severe anemia, syphilis, chemotherapy, corticosteroid therapy, sickle cell disease, acquired immunodeficiency syndrome, old age, malnutrition, smoking and alcohol consumption, radiotherapy, osteoporosis, Paget's disease of bone ...
Osteosclerosis is a disorder characterized by abnormal hardening of bone and an elevation in bone density. It may predominantly affect the medullary portion and/or cortex of bone.